Ken is a seasoned executive with M&A experience in selling two software companies that he helped found. Ken led these companies to successful acquisitions by publicly traded Platinum Technology and IBM, and he led additional acquisitions for them.
He then joined CFA in 2016 where he worked on several more transactions across industries including IT and Pharma.
Ken is on the board of the Band of Parents where he and the board helped bring several new treatment options directly to the clinic including a drug called Naxitamab Danyelza. In 2021, The FDA approved the drug naxitamab (Danyelza) for the treatment of patients with high-risk neuroblastoma.
